In a report released today, Craig Hettenbach from Morgan Stanley maintained a Buy rating on Omada Health, Inc., with a price target of $25.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Craig Hettenbach has given his Buy rating due to a combination of factors that highlight Omada Health, Inc.’s potential for growth and profitability. The company’s stock has shown technical weakness, breaking below its IPO price, which presents an attractive risk/reward scenario ahead of what is expected to be a strong second-quarter earnings report. This anticipated earnings performance is crucial for converting robust revenue growth into EBITDA gains, which could drive the stock towards the price target of $25, representing a significant upside.
Furthermore, Omada Health is seen as a leader within the Digital Health 2.0 framework, with a favorable 3:1 Bull/Bear ratio. The stock is currently trading at a lower EV/S/G multiple compared to its healthcare IT and SMID software peers, making it an appealing entry point for investors. Despite skepticism in the digital health sector, Omada’s stock performance reflects positive investor sentiment regarding its growth durability and ability to scale profitably. The company’s upcoming earnings report is viewed as an opportunity to demonstrate growth and margin improvements, potentially shifting market sentiment favorably.
In another report released on July 1, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $20.00 price target.